Glucagon Is Produced in the Pancreas: Key Peptide Product Composition Insight
Abstract: Glucagon, a 29-amino acid peptide, is produced in pancreatic alpha cells. The global peptide therapeutics market, valued at $40.5 billion in 2023, is projected to grow at a CAGR of 8.9% through 2030. Key brands like Novo Nordisk’s GlucaGen and Xeris’s Gvoke differ in formulation stability (liquid vs. lyophilized) and delivery (auto-injector vs. prefilled syringe). Liquid stable glucagon (Gvoke) offers superior reconstitution-free convenience but higher cost. Peptide products require GMP-certified facilities (e.g., FDA/EMA audits) and cold-chain logistics (2-8°C). Selection criteria prioritize purity (>98% HPLC), bioactivity, and regulatory compliance (USP/Ph.Eur.). Industry trends emphasize non-injectable analogs and diabetes-obesity convergence.